摘要
Human umbilical cord mesenchymal stem cells (hUC-MSCs) are a promising candidate for spinal cord injury (SCI) repair owing to their advantages of low immunogenicity and easy accessibility over other MSC sources. However, modest clinical efficacy hampered the progression of these cells to clinical translation. This discrepancy may be due to many variables, such as cell source, timing of implantation, route of administration, and relevant efficacious cell dose, which are critical factors that affect the efficacy of treatment of patients with SCI. Previously, we have evaluated the safety and efficacy of 4 x 10(6) hUC-MSCs/kg in the treatment of subacute SCI by intrathecal implantation in rat models. To search for a more accurate dose range for clinical translation, we compared the effects of three different doses of hUC-MSCs - low (0.25 x 10(6) cells/kg), medium (1 x 10(6) cells/kg) and high (4 x 10(6) cells/kg) - on subacute SCI repair through an elaborate combination of behavioral analyses, anatomical analyses, magnetic resonance imaging-diffusion tensor imaging (MRI-DTI), biotinylated dextran amine (BDA) tracing, electrophysiology, and quantification of mRNA levels of ion channels and neurotransmitter receptors. Our study demonstrated that the medium dose, but not the low dose, is as efficient as the high dose in producing the desired therapeutic outcomes. Furthermore, partial restoration of the gamma-aminobutyric acid type A (GABA(A)) receptor expression by the effective doses indicates that GABA(A) receptors are possible candidates for therapeutic targeting of dormant relay pathways in injured spinal cord. Overall, this study revealed that intrathecal implantation of 1 x 10(6) hUC-MSCs/kg is an alternative approach for treating subacute SCI.
学科与关键词
- hUC-MSC-mediated recovery of subacute spinal cord injury through enhancing the pivotal subunits β3 and γ2 of the GABAA receptorCao, Tingting; Chen, Huan; Huang, Weiping; Xu, Sisi; Liu, Peilin; Zou, Weiwei; Pang, Mao; Xu, Ying; Bai, Xiaochun; Liu, Bin; Rong, Limin; Cui, Zhong-Kai*; Li, Mangmang*2022, 12(7): 3057-3078.被引 17
- Clinical observation of umbilical cord mesenchymal stem cell transplantation in treatment for sequelae of thoracolumbar spinal cord injuryCheng Hongbin; Liu Xuebin; Hua Rongrong; Dai Guanghui; Wang Xiaodong; Gao Jianhua; An Yihua*Journal of Translational Medicine, 2014, 12: 253.被引 1
- Multimodal Repair of Spinal Cord Injury With Mesenchymal Stem CellsMa, Yuan-huan; Liang, Qing-yue; Ding, Ying; Han, Inbo; Zeng, Xiang*Neurospine, 2022, 19(3): 616-629.被引 6
